Page last updated: 2024-11-13

holothurin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

holothurin A: RN given refers to Na salt (3 beta,12 alpha,22S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23675050
SCHEMBL ID241238
MeSH IDM0106821

Synonyms (9)

Synonym
lanost-9(11)-en-18-oic acid, 22,25-epoxy-12,17,20-trihydroxy-3-((o-3-o-methyl-beta-d-glucopyranosyl-(1-3)-o-beta-d-glucopyranosyl-(1-4)-o-6-deoxy-beta-d-glucopyranosyl-(1-2)-4-o-sulfo-beta-d-xylopyranosyl)oxy)-, gamma-lactone, monosodium salt, (3-beta,12-
holothurin a
11-keto-boswellic acid
38-26-6
unii-1ev65qt62c
1ev65qt62c ,
SCHEMBL241238
DTXSID601018905
Q27252335

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" However, the pharmacokinetic profile of its anti-inflammatory bioactive compounds has not been elucidated."( Comparative pharmacokinetic study of two boswellic acids in normal and arthritic rat plasma after oral administration of Boswellia serrata extract or Huo Luo Xiao Ling Dan by LC-MS.
Ai, Y; Dai, R; Lee, DY; Wang, H; Wu, Y; Zhang, C, 2014
)
0.4
" This paper describes the comparisons in plasma pharmacokinetic behaviors of 11-keto-β-boswellic acid (KBA) and 3-acetyl-11-keto-β-boswellic acid (AKBA) in FRA and its processed products, and their effects on coagulation factors and blood clotting tetrachoric, using an acute cold blood-stasis animal model after oral administration of FRA, SFF, and VPF."( Comparative studies of pharmacokinetics and anticoagulatory effect in rats after oral administration of Frankincense and its processed products.
Hua, HM; Liang, XX; Liu, XQ; Meng, DY; Niu, LY; Pan, YN; Tong, X; Wang, YN; Zheng, J, 2015
)
0.42
"For pharmacokinetic study, Sprague-Dawley (SD) rats were randomly divided into three groups, including group FRA, group SFF and group VPF."( Comparative studies of pharmacokinetics and anticoagulatory effect in rats after oral administration of Frankincense and its processed products.
Hua, HM; Liang, XX; Liu, XQ; Meng, DY; Niu, LY; Pan, YN; Tong, X; Wang, YN; Zheng, J, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" serrata extract may be enhanced by increasing the bioavailability of AKBA."( Metabolism of boswellic acids in vitro and in vivo.
Abdel-Tawab, M; Bahr, U; Daneshfar, R; Eckert, GP; Karas, M; Klein, J; Krüger, P; Müller, WE; Schubert-Zsilavecz, M; Volmer, DA, 2008
)
0.35
" In continuation of the tests investigating the factors limiting bioavailability of boswellic acids, the present study examined the permeability of KBA and AKBA in human Caco-2 cell lines."( Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2.
Abdel-Tawab, M; Fricker, G; Hummel, J; Kanzer, J; Krüger, P; Schubert-Zsilavecz, M, 2009
)
0.35
"7 mg l⁻¹ day⁻¹ of the main product, 7β-hydroxy-KBA, could be obtained thus providing a suitable starting point for the efficient production of modified KBA by chemical tailoring to produce novel KBA derivatives with increased bioavailability and this way more efficient drugs."( A new cytochrome P450 system from Bacillus megaterium DSM319 for the hydroxylation of 11-keto-β-boswellic acid (KBA).
Bernhardt, R; Brill, E; Brüning, G; Hannemann, F; Jauch, J; Zapp, J, 2014
)
0.4
" Taken as whole, the major permeability related hurdles that hampered oral bioavailability of KBA included its gastrointestinal instability, CYP3A4 mediated intestinal metabolism, accumulation within the enterocytes and saturable kinetics."( Investigating permeability related hurdles in oral delivery of 11-keto-β-boswellic acid.
Bagul, P; Bansal, AK; Khomane, KS, 2014
)
0.4
"The observed improvement of anticoagulation by processed FRA may result from the increased absorption and bioavailability of triterpenoids."( Comparative studies of pharmacokinetics and anticoagulatory effect in rats after oral administration of Frankincense and its processed products.
Hua, HM; Liang, XX; Liu, XQ; Meng, DY; Niu, LY; Pan, YN; Tong, X; Wang, YN; Zheng, J, 2015
)
0.42
"To evaluate the effect of ritonavir (RTV) co-administration on the bioavailability of an amorphous dispersion of acetyl-11-keto-beta-boswellic acid (AKBA) and to develop a pharmaceutically acceptable AKBA-RTV combination tablet."( Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.
Brough, C; Cisneros, M; Ellenberger, DJ; Keen, JM; McGinity, JW; Miller, DA; Williams, RO, 2016
)
0.43
"A pharmacokinetic (PK) study in rats was conducted to evaluate the influence of RTV co-administration on the oral bioavailability of an AKBA amorphous dispersion."( Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.
Brough, C; Cisneros, M; Ellenberger, DJ; Keen, JM; McGinity, JW; Miller, DA; Williams, RO, 2016
)
0.43
" The AKBA-RTV combination tablets yielded a substantial increase in AKBA's bioavailability in dogs."( Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.
Brough, C; Cisneros, M; Ellenberger, DJ; Keen, JM; McGinity, JW; Miller, DA; Williams, RO, 2016
)
0.43
" Consequently, AKBA's oral bioavailability is maximized by administration from a supersaturating formulation in conjunction with a CYP3A inhibitor."( Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.
Brough, C; Cisneros, M; Ellenberger, DJ; Keen, JM; McGinity, JW; Miller, DA; Williams, RO, 2016
)
0.43
" Anti-inflammatory activity of 11-keto-β-boswellic acid (KBA) is impeded by poor oral bioavailability due to its high lipid solubility, rapid phase-1 metabolism and poor intestinal permeability."( Nanoparticle formulation of 11-keto-β-boswellic acid (KBA): anti-inflammatory activity and in vivo pharmacokinetics.
Bairwa, K; Jachak, SM, 2016
)
0.43
"This study developed a poly-dl-lactide-co-glycolide-based nanoparticle formulation of KBA to improve its oral bioavailability and in vivo anti-inflammatory activity."( Nanoparticle formulation of 11-keto-β-boswellic acid (KBA): anti-inflammatory activity and in vivo pharmacokinetics.
Bairwa, K; Jachak, SM, 2016
)
0.43
"The results of improved oral bioavailability and in vivo anti-inflammatory activity of KBA-NPs suggested successful development of KBA nanoparticle formulation."( Nanoparticle formulation of 11-keto-β-boswellic acid (KBA): anti-inflammatory activity and in vivo pharmacokinetics.
Bairwa, K; Jachak, SM, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (11.29)18.7374
1990's0 (0.00)18.2507
2000's9 (14.52)29.6817
2010's35 (56.45)24.3611
2020's11 (17.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.69 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.94%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other66 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]